Skip to content

Feed Screener MCP Methodology

⌘K

EN

Pricing Sign in

InsiderLens

Statistics predict. AI explains.

Insider transactions from public regulatory disclosures, aggregated and enriched with deterministic statistical signals. Not investment advice.

Sources

SEC EDGAR · US
AMF · FR
BAFIN · DE

Product

Methodology
Signal backtests
Privacy notice
Object to processing

Language

English Español Français

Feed Screener MCP Methodology

English Español Français

Pricing Sign in

Ahlers James M — Cue Biopharma, Inc. insider: 2 transactions · InsiderLens

/ / Ahlers James M

Ahlers James M

Executive VP of CF at INTENSITY THERAPEUTICS, INC. · on record since Jun 29, 2023
Chief Financial Officer at RenovoRx, Inc. · on record since Jul 20, 2022
VP Fin & Op & CFO at INTARCIA THERAPEUTICS, INC · on record since Sep 20, 2005
Chief Financial Officer at Cue Biopharma, Inc. · on record since Aug 3, 2026

Insider trading activity of Ahlers James M

Transactions on record: 2; since Aug 3, 2026

Open-market buys: 0

Open-market sells: 0

Companies traded: 1; last filing Aug 3, 2026

Figures computed from official regulatory filings — .

Companies where Ahlers James M has traded

Cue Biopharma, Inc.2 tx · Aug 3, 2026

Track record of Ahlers James M

Insufficient history for a statistical track record (fewer than 5 open-market buys).

Transaction history of Ahlers James M

Co-insiders of Ahlers James M

Agah RamtinRenovoRx, Inc.
Alessi Thomas RINTARCIA THERAPEUTICS, INC
ALTA BIOPHARMA MANAGEMENT II LLCINTARCIA THERAPEUTICS, INC
ALTA BIOPHARMA PARTNERS II LPINTARCIA THERAPEUTICS, INC
ALTA CALIFORNIA MANAGEMENT PARTNERS II LLCINTARCIA THERAPEUTICS, INC
Alta California Management Partners II, LLC -- New PoolINTARCIA THERAPEUTICS, INC
ALTA CALIFORNIA PARTNERS II LPINTARCIA THERAPEUTICS, INC
Alta California Partners II, L.P. -- New PoolINTARCIA THERAPEUTICS, INC
ALTA EMBARCADERO BIOPHARMA PARTNERS II LLCINTARCIA THERAPEUTICS, INC
ALTA EMBARCADERO PARTNERS II LLCINTARCIA THERAPEUTICS, INC
ALTA PARTNERSINTARCIA THERAPEUTICS, INC
ALTA PARTNERS II INCINTARCIA THERAPEUTICS, INC
Azam UsmanCue Biopharma, Inc.
Bagai ShaunRenovoRx, Inc.
Baker Daniel G.Cue Biopharma, Inc.
BANK OF THE WESTRenovoRx, Inc.
BARRETT M JAMESINTARCIA THERAPEUTICS, INC
BARRIS PETER JINTARCIA THERAPEUTICS, INC
BENDER LEWIS HINTENSITY THERAPEUTICS, INC.
Blanchett Dennis GINTARCIA THERAPEUTICS, INC
Borie Dominique ChristianCue Biopharma, Inc.
Camardo Daniel A.Cue Biopharma, Inc.
CHAMPSI FARAHINTARCIA THERAPEUTICS, INC

This page republishes public regulatory disclosures.

Chaparro RodolfoCue Biopharma, Inc.

Church Jill MarieCue Biopharma, Inc.

DELEAGE JEANINTARCIA THERAPEUTICS, INC

DIAMOND DAVIDRenovoRx, Inc.

DIGIANDOMENICO ANTHONYCue Biopharma, Inc.

Donovan DanielINTENSITY THERAPEUTICS, INC.

DRISCOLL FREDERICK WCue Biopharma, Inc.

DUBIN THOMAS I HINTENSITY THERAPEUTICS, INC.

EBERSMAN DAVID AINTARCIA THERAPEUTICS, INC

Fletcher Aaron G.L.Cue Biopharma, Inc.

Fox Michael JCue Biopharma, Inc.

Garzone PamelaCue Biopharma, Inc.

Gentry LeesaRenovoRx, Inc.

GOLDBERG MARK AINTENSITY THERAPEUTICS, INC.

Gray CameronCue Biopharma, Inc.

GRUENER GARRETTINTARCIA THERAPEUTICS, INC

HOWSON TAMAR DCue Biopharma, Inc.

JANNEY DANIELINTARCIA THERAPEUTICS, INC

Kellman Joel DINTARCIA THERAPEUTICS, INC

Kiener Peter ACue Biopharma, Inc.

Kocak RonRenovoRx, Inc.

KRAMLICH C RICHARDINTARCIA THERAPEUTICS, INC

LANGECKER PETERINTARCIA THERAPEUTICS, INC

Leahy EmerINTENSITY THERAPEUTICS, INC.

Lehman Christopher JohnRenovoRx, Inc.

LEUNG KARLING ALICEINTARCIA THERAPEUTICS, INC

Levisetti MatteoCue Biopharma, Inc.

Concerned by this data? Exercise your right to object →

Company	Filed	Type	Qty	Price	Value · USD	Src	Details
Cue Biopharma, Inc.	Aug 3, 2026	Award	25,500	0.00 USD	—	SEC
Cue Biopharma, Inc.	Aug 3, 2026	AwardD (derivative)	51,000	0.00 USD	—	SEC